美國癌癥聯合委員會膽囊癌分期系統（第 8 版）更新的多學科解讀_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

孔煒偉 ¹ , 陳駿 ² , 何健 ³ , 毛諒 ⁴ ,  仇毓東 ⁴

1. ;
2. ;
3. ;
4. ;

Corresponding?author：

仇毓東, Email: yudongqiu510@163.com

Keywords：

DOI：

10.7507/1007-9424.201708074

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 孔煒偉, 陳駿, 何健, 毛諒, 仇毓東. 美國癌癥聯合委員會膽囊癌分期系統（第 8 版）更新的多學科解讀. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(9): 1053-1056. doi: 10.7507/1007-9424.201708074 Copy

1.	Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol, 2014, 6: 99-109.
2.	Amin MB. AJCC Cancer Staging Manual. 8^th ed. New York: Springer, 2017: 303-309.
3.	Coburn NG, Cleary SP, Tan JC, et al. Surgery for gallbladder cancer: a population-based analysis. J Am Coll Surg, 2008, 207(3): 371-382.
4.	李斌, 劉辰, 姜小清. 膽囊癌規范化診治專家共識 (2016). 臨床肝膽病雜志, 2017, 22(4): 721-728.
5.	Sternby Eilard M, Lundgren L, Cahlin C, et al. Surgical treatment for gallbladder cancer—a systematic literature review. Scand J Gastroenterol, 2017, 52(5): 505-514.
6.	Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg, 2015, 261(4): 733-739.
7.	Lee W, Jeong CY, Jang JY, et al. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery, 2017, 162(3): 515-524.
8.	Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol, 2010, 17(7): 1831-1840.
9.	Amini N, Kim Y, Wilson A, et al. Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Ann Surg Oncol, 2016, 23(9): 3016-3023.
10.	Bach AM, Loring LA, Hann LE, et al. Gallbladder cancer: can ultrasonography evaluate extent of disease? J Ultrasound Med, 1998, 17(5): 303-309.
11.	Yoshimitsu K, Honda H, Shinozaki K, et al. Helical CT of the local spread of carcinoma of the gallbladder: evaluation according to the TNM system in patients who underwent surgical resection. AJR Am J Roentgenol, 2002, 179(2): 423-428.
12.	Ohtani T, Shirai Y, Tsukada K, et al. Carcinoma of the gallbladder: CT evaluation of lymphatic spread. Radiology, 1993, 189(3): 875-880.
13.	Kim JH, Kim TK, Eun HW, et al. Preoperative evaluation of gallbladder carcinoma: efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging, 2002, 16(6): 676-684.
14.	Morine Y, Shimada M, Imura S, et al. Detection of Lymph Nodes Metastasis in Biliary Carcinomas: Morphological Criteria by MDCT and the Clinical Impact of DWI-MRI. Hepatogastroenterology, 2015, 62(140): 777-781.
15.	Leung U, Pandit-Taskar N, Corvera CU, et al. Impact of pre-operative positron emission tomography in gallbladder cancer. HPB (Oxford), 2014, 16(11): 1023-1030.
16.	Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol, 2012, 30(16): 1934-1940.
17.	Ma N, Cheng H, Qin B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer, 2015, 15: 615.
18.	Mitin T, Enestvedt CK, Jemal A, et al. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst, 2017, 109(7): djw324.
19.	Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study.J Clin Oncol, 2017, 35(Suppl): abstr 4006.
20.	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
21.	Woo SM, Lee SH, Yoo JW, et al. A Multicenter Phase Ⅱ Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer. Gut Liver, 2013, 7(5): 594-598.
22.	Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase Ⅱ Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol, 2015, 33(24): 2617-2622.
23.	Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol, 2007, 96(1): 8-13.
24.	Norton RA, Foster EA. Bile duct cancer. CA Cancer J Clin, 1990, 40(4): 225-233.

1. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol, 2014, 6: 99-109.
2. Amin MB. AJCC Cancer Staging Manual. 8^th ed. New York: Springer, 2017: 303-309.
3. Coburn NG, Cleary SP, Tan JC, et al. Surgery for gallbladder cancer: a population-based analysis. J Am Coll Surg, 2008, 207(3): 371-382.
4. 李斌, 劉辰, 姜小清. 膽囊癌規范化診治專家共識 (2016). 臨床肝膽病雜志, 2017, 22(4): 721-728.
5. Sternby Eilard M, Lundgren L, Cahlin C, et al. Surgical treatment for gallbladder cancer—a systematic literature review. Scand J Gastroenterol, 2017, 52(5): 505-514.
6. Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg, 2015, 261(4): 733-739.
7. Lee W, Jeong CY, Jang JY, et al. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery, 2017, 162(3): 515-524.
8. Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently determines the prognosis after resection in patients with gallbladder carcinoma. Ann Surg Oncol, 2010, 17(7): 1831-1840.
9. Amini N, Kim Y, Wilson A, et al. Prognostic Implications of Lymph Node Status for Patients With Gallbladder Cancer: A Multi-Institutional Study. Ann Surg Oncol, 2016, 23(9): 3016-3023.
10. Bach AM, Loring LA, Hann LE, et al. Gallbladder cancer: can ultrasonography evaluate extent of disease? J Ultrasound Med, 1998, 17(5): 303-309.
11. Yoshimitsu K, Honda H, Shinozaki K, et al. Helical CT of the local spread of carcinoma of the gallbladder: evaluation according to the TNM system in patients who underwent surgical resection. AJR Am J Roentgenol, 2002, 179(2): 423-428.
12. Ohtani T, Shirai Y, Tsukada K, et al. Carcinoma of the gallbladder: CT evaluation of lymphatic spread. Radiology, 1993, 189(3): 875-880.
13. Kim JH, Kim TK, Eun HW, et al. Preoperative evaluation of gallbladder carcinoma: efficacy of combined use of MR imaging, MR cholangiography, and contrast-enhanced dual-phase three-dimensional MR angiography. J Magn Reson Imaging, 2002, 16(6): 676-684.
14. Morine Y, Shimada M, Imura S, et al. Detection of Lymph Nodes Metastasis in Biliary Carcinomas: Morphological Criteria by MDCT and the Clinical Impact of DWI-MRI. Hepatogastroenterology, 2015, 62(140): 777-781.
15. Leung U, Pandit-Taskar N, Corvera CU, et al. Impact of pre-operative positron emission tomography in gallbladder cancer. HPB (Oxford), 2014, 16(11): 1023-1030.
16. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol, 2012, 30(16): 1934-1940.
17. Ma N, Cheng H, Qin B, et al. Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis. BMC Cancer, 2015, 15: 615.
18. Mitin T, Enestvedt CK, Jemal A, et al. Limited Use of Adjuvant Therapy in Patients With Resected Gallbladder Cancer Despite a Strong Association With Survival. J Natl Cancer Inst, 2017, 109(7): djw324.
19. Primrose JN, Fox R, Palmer DH, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study.J Clin Oncol, 2017, 35(Suppl): abstr 4006.
20. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
21. Woo SM, Lee SH, Yoo JW, et al. A Multicenter Phase Ⅱ Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer. Gut Liver, 2013, 7(5): 594-598.
22. Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: A Phase Ⅱ Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol, 2015, 33(24): 2617-2622.
23. Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. J Surg Oncol, 2007, 96(1): 8-13.
24. Norton RA, Foster EA. Bile duct cancer. CA Cancer J Clin, 1990, 40(4): 225-233.

Previous Article
侵犯第二、三肝門肝包蟲病的外科治療
Next Article
Surgical resection of liver masses involving the second and the third porta hepatis: a report of 13 cases

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

美國癌癥聯合委員會膽囊癌分期系統（第 8 版）更新的多學科解讀

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content